Editors Note:

The Nasdaq Composite lost -3.2% for the week and impacted all of our tech positions. This decline should be temporary ahead of the Q3 earnings but we never know until it is past tense.

In theory, investing in LEAPS is a long-term proposition where we hold over earnings in anticipation of a long-term gain. LEAPS should be exited in the normal November rally.



Original Play Recommendations (Alpha by Symbol)


ABBV - AbbVie - Company Profile

Comments:

Three scientists who were crucial to developing Humira were honored with a Nobel Price. The body said researchers have "taken control of evolution and used it for purposes that bring the greatest benefit to mankind." They have forced the evolution process to develop everything from biofuels to pharmaceuticals.

Original Trade Description: February 11th.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. Company description from FinViz.com.

A lot of companies have 1-2 real drugs in the pipeline that may be approved. Several companies have one drug that could be a blockbuster and reach $1 billion in sales annually. AbbVie has multiple blockbusters in the pipeline and dozens of other drugs already in the market.

AbbVie was a spinoff from Abbott Laboratories in 2012 and they are doing great. The company reported Q4 adjusted earnings of $1.48 compared to estimates for $1.44. Revenue of $7.74 billion beat estimates for $7.57 billion. They guided for full year earnings in the range of $7.33-$7.43 per share, up from $6.37-$6.57. The FactSet consensus estimate was $6.66. The company said it planned to invest $2.5 billion in US capital projects and a possible expansion to its US facilities. Sales of Humira, Imbruvica, Lupron, Creon, Synagis, Kaletra, Sevoflurane and Duodopa all came in above expectations. Shares spiked $15 on the news.

The company's many new drugs are going to be cash cows. Imbruvica generated $1.8 billion in sales in 2016 and could reach $7 billion annually over the next couple of years. Venclexta was approved in 2016 for leukemia and sales could peak at $3.5 billion a year. An experimental cancer drug called Rova-T could hit $5 billion a year when approved. A psoriasis drug called risankizumab could produce $4 billion a year and arthritis drug upadacitinib could peak at $3.5 billion.

AbbVie's drug Humira is expected to sell more than $20 billion in 2018 after a $18 billion revenue in 2017. The FDA has 10 FDA approved indications giving it a massive patient base. This is just one of AbbVie's billion dollar blockbuster drugs. AbbVie and Amgen reached an agreement on a biosimilar for Humira. Amgen can sell its copy in the US starting Jan 23rd, 2023 and several European countries on Oct 16th, 2018. Amgen will pay royalties to AbbVie for the marketing rights. Both parties canceled legal proceedings regarding existing patents. The marketing agreement grants "non-exclusive" right, which suggests AbbVie will repeat the same agreement with other companies and thereby guaranteeing future royalty streams.

AbbVie has declared war on the Gilead Sciences Hep-C franchise. The AbbVie drug Mavyret has a 97.5% cure rate and only costs $13,200 for four weeks of treatment compared to Gilead's newest drugs at $25,000 for four-weeks. Most patients are cured in 8 weeks but some have to continue for 12 weeks. Gilead's Harvoni was initially $96,000 for a 12-week treatment.

Here is the key point for AbbVie. The company said non-Humira sales are expected to rise from $9.6 billion in 2017 to $35 billion by 2025. The company is launching 20 additional products by 2020 with at least 8 of them expected to generate more than $1 billion in annual sales. These drugs will focus on Alzheimers, women's health and Hepatitis C.

Update 9/16: AbbVie shares rose after the company released positive data on multiple drugs from multiple studies. Hopefully investors will remember that AbbVie ia going to be a money printing machine. Our Jan 2019 $120 call has evaporated to nothing with ABBV at $95. You could sell a Jan $110 call, currently to turn that into a spread. The call is $1.04 today. That gets some of our money back.

Update 9/23: Shares were crushed again after California filed suit against the company claiming they were giving kickbacks to doctors to induce them to prescribe Humira. The suit claims AbbVie paid for travel, meals, etc for doctors attending medical conferences.

Update 9/30: Shares rebounded from the news on the California suit to touch $95 again. Earlier in the week Gilead cut the price of its Hep-C drug to $24,000 from more than $75,000 and there was some volatility on that announcement. However, analysts said the generic play by Gilead simply re-priced the drugs as generics to about the actual price they were receiving after discounts and rebates. The marketing ploy should not impact AbbVie's Hep-C drug sales.

Position 2/12/18:
Long Jan 2019 $120 LEAP Call @ $8.50, see portfolio graphic for stop loss.
Position 3/26/18:
Long Jan 2019 $120 LEAP Call @ $3.30.
Adjusted cost now $5.90.

Position 7/30/18:
Long Jan 2020 $100 call @ $7.70, see portfolio graphic for stop loss.



ADBE - Adobe Systems - Company Profile

Comments:

No specific news. Shares dropped back to the 60-day average again. This is an entry point if you are not already in the position or want to add to it.

Original Trade Description: Aug 19th

Adobe Systems Incorporated operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content. Its flagship product is Creative Cloud, a subscription service that allows customers to download and install the latest versions of its creative products. This segment serves traditional content creators, Web application developers, and digital media professionals, as well as their management in marketing departments and agencies, companies, and publishers. The company's Digital Marketing segment offers solutions for how digital advertising and marketing are created, managed, executed, measured, and optimized. This segment provides analytics, social marketing, targeting, media optimization, digital experience management, cross-channel campaign management, audience management, and video delivery and monetization solutions to digital marketers, advertisers, publishers, merchandisers, Web analysts, chief marketing officers, chief information officers, and chief revenue officers. Its Print and Publishing segment offers products and services, such as e-learning solutions, technical document publishing, Web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company markets and licenses its products and services directly to enterprise customers through its sales force, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, independent software vendors, retailers, and OEMs. The company was founded in 1982 and is headquartered in San Jose, California. Company description from FinViz.com.

Adobe reported earnings of $1.66 compared to estimates for $1.54. Revenue of $2.20 billion beat estimates for $2.16 billion. They guided for the current quarter for earnings of $1.68 on revenue of $2.24 billion. Analysts were expecting $1.61 and $2.23 billion. Adobe said it would have a 7% tax rate in Q3/Q4. They guided for 25% growth in Q3 in the Digital Media division, which contributes 70% of revenue. Analysts were expecting 23.4%.

Shares declined after the company said Q3 is seasonally weak but Q4 is seasonally strong. The new acquisition, Magneto, is expected to contribute $40 million in revenue in those two quarters.

They recently partnered with Microsoft and this is expected to provide a significant boost to revenue and earnings in the coming year.

Earnings are September 13th. I hesitated to jump into this position ahead of earnings less than a month out but the stock is depressed and expectations are low. There is a chance for a positive surprise.

Adobe options are very expensive and I am only going to reach out to January. We have to take small bites in this stock over the next 18 months.

Update 9/16: Adobe (ADBE) reported earnings Thursday evening of $1.73 and analysts were expecting $1.69. Revenue of $2.29 billion beat estimates for $2.25 billion. Shares fell $2 in afterhours but exploded higher on Friday to gain $6.

Update 9/23: Adobe said it was acquiring Marketo for $4.75 billion. Marketo makes business marketing software. The company was public but was acquired by Vista Equita for $1.8 billion in 2016. That is a great return for Vista. Adobe will put the Marketo products in their Experience Cloud. The deal could close this fiscal quarter. This is the largest purchase in Adobe's history. Marketo had $320 million in revenue in 2017 and expects 20% revenue growth in 2018. This acquisition was to help Adobe better compete with Salesforce.com. Shares declined on the idea that Adobe paid too much.

Position 8/20/18:
Long Jan $260 call @ $12.25, see portfolio graphic for stop loss.
Short Jan $285 call @ $5.00, see portfolio graphic for stop loss.
Net debit $7.25.


BB - BlackBerry Company Profile

Comments:

BlackBerry said they had added a quantum-resistant code signing server to its array of cryptography tools. Quantum computers are only in the testing stages but BlackBerry said if you want your hardware and software developed today to still be secure 10-15 years from now you have to use a quantum resistant tool. Quantum computers are expected to be a evolutionary leap from today's technology and be able to crack today's encrypted data. Developers will have to use a significantly larger key to keep data safe.

Original Trade Description: April 1st.

BlackBerry Limited operates as security software and services company in securing, connecting, and mobilizing enterprises worldwide. The company operates in three segments: Software & Services, Mobility Solutions, and Service Access Fees (SAF). The Software & Services segment offers enterprise software and services, including mobile-first security, productivity, collaboration, and end-point management solutions for the Enterprise of Things through the BlackBerry Secure platform; BlackBerry technology solutions, such as BlackBerry QNX, Certicom, Paratek, BlackBerry Radar, and intellectual property and licensing; AtHoc, which provides secure, networked crisis communications solutions; SecuSmart that offers secure voice and text messaging solutions with encryption and anti-eavesdropping facilities; licensing and services related to BlackBerry Messenger; and cybersecurity consulting services and tools. The Mobility Solutions segment engages in the development and licensing of secure device software and the outsourcing to partners of design, manufacturing, sales, and customer support for BlackBerry-branded handsets. This segment also develops software updates for its legacy BlackBerry 10 platform, and delivers BlackBerry productivity applications to Android smartphone users via the Google Play store; and sells its DTEK60, DTEK50, Priv, Leap, and Passport smartphones and smartphone accessories, as well as offers non-warranty repair services. The SAF segment consists of operations related to subscribers using mobile devices with its legacy BlackBerry 7 and prior operating systems. The company was formerly known as Research In Motion Limited and changed its name to BlackBerry Limited in July 2013. BlackBerry Limited was founded in 1984 and is headquartered in Waterloo, Canada. Company description from FinViz.com

BlackBerry reported adjusted earnings of 5 cents that beat analyst estimates for a breakeven. Revenue fell 18.5% to $233 million. Revenue from software and services rose 19% to $108 million. Gross margins rose from 60.1% to 76%. The company has about 3,500 enterprise customers and expects software and services billings to grow by double digits. The stock was slammed on the lack of concrete guidance. BlackBerry is transitioning customers to a subscription model and that depresses earnings for the first 18 months of a transition but provides more stable earnings in the future.

BlackBerry started out as a smartphone manufacturer under the name Research in Motion (RIMM). Over the years they failed to keep pace with Apple and Android and the BlackBerry phones are now just a niche market and they contract with another company to have them made.

BlackBerry has evolved into a software and services company with security software, mobility solutions, and dozens of other categories. The company is now the largest provider of automobile operating systems with tens of millions of cars using their QNX software.

They are using their experience in auto OS to build the next generation of autonomous vehicles. They announced last week that Baidu had chosen them to help develop self-driving technology. Baidu said "by integrating the QNX OS with the Apollo platform, we will enable carmakers to leap from prototype to production systems." BlackBerry radar, an asset tracking solution, is already available at more than 2,800 heavy-duty truck dealerships across North America. This software and equipment tracks trucks, loads, trailers, containers, heavy machinery and other transportation assets. Trucking companies and shippers can track the location of their cargo and vehicles in real time all the time.

There are rumors in the market that BlackBerry could suddenly become an acquisition target because of their small size of $8 billion market cap and vast array of growing software services. This is not some new fad company. There is history and there is a remarkable turnaround in progress.

BlackBerry recently launched a product called BlackBerry Jarvis. This is anti hacking software for self driving cars. Manufacturers can use it to scan their product before they are released to look for weak points that could be hacked. Tata Motors said the product allowed them to cut the analysis time down from 30 days to 7 minutes.

BlackBerry is suing Facebook on patent violations after years of negotiations on the topic. BlackBerry contends that the WhatsApp and other Facebook features violate their patents from the early days when Research in Motion was the biggest maker of smartphones. Negotiations broke down because of the monetary size of the problem. This could be a real windfall for BlackBerry but it could be years from now before the case will be settled.

I believe BlackBerry will either rise from the ashes of the telephone handset market or be acquired by any number of possible suitors. BlackBerry has thousands of patents that are probably worth almost as much as their market cap. They are a rapidly expanding business and they will be noticed. I am recommending we take advantage of their post earnings dip to look long term and be greedy when others are fearful.

Update 9/16: BB shares rallied on the new ultra secure BlackBerry Spark for the Enterprise of Things (EOT) platform. They claim hyper security from the kernel to the edge. (Server to the IoT device) Given the new trend for hackers to invade and take control of all kinds of IoT devices like cameras, thermostats, refrigerators, etc, and then use those devices for Denial of Service (DoS) attacks, this is a good application.

Update on last week's Facebook countersuit problem. BB has 44,000 smartphone patents. License fees accounted for 30% of its revenue in Q2. Facebook may win on several of its counter claims but Blackberry should come out the overall winner years from now.

Update 9/30: BlackBerry reported earnings of 4 cents that easily beat estimates for a penny. This compares to a loss of 8 cents in the year ago quarter. Revenue of $210 million beat estimates for $206 million. The company reaffirmed guidance for "positive" adjusted EPS and revenue growth for software and services of 8% to 10%. Approximately 81% of the revenue in that division was recurring subscription revenue. Cash on hand was $2.4 billion. BlackBerry is prospering now that their software operating system is used in a large number of high-end new cars. I see them as takeover bait.

Position 4/2/18:
Long Jan 2020 $12.50 LEAP Call @ $2.32, see portfolio graphic for stop loss.



C - Citigroup - Company Profile

Comments:

Still no trend for financials. Citi will report earnings next Friday.

Original Trade Description: March 18th.

Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions. The company operates through two segments, Global Consumer Banking (GCB) and Institutional Clients Group (ICG). The GCB segment offers traditional banking services to retail customers through retail banking, commercial banking, Citi-branded cards, and Citi retail services. It also provides various banking, credit card lending, and investment services through a network of local branches, offices, and electronic delivery systems. The ICG segment provides wholesale banking products and services, including fixed income and equity sales and trading, foreign exchange, prime brokerage, derivative services, equity and fixed income research, corporate lending, investment banking and advisory services, private banking, cash management, trade finance, and securities services to corporate, institutional, public sector, and high-net-worth clients. The company operates in North America, Latin America, Asia, Europe, the Middle East, and Africa. Citigroup Inc. was founded in 1812 and is based in New York, New York. Company description from FinViz.com.

This is going to be a really short play description. Nearly every banking analyst has Citigroup as one of their top picks because they have been so disrespected over the last six months. The stock has been trading sideways despite having outstanding assets, clients, deposits and a growing loan base. The analysts claim investors are remembering the poor management in years past and the serious trouble they had coming out of the financial crisis.

All of that is behind them and they have only good times ahead. With the Fed raising interest rates their income is going to explode. They took more than $20 billion in noncash charges in Q4 earnings as a result of the tax reform. That is now behind them and they expect earnings to improve because of their lower tax rate. They bought back 74 million shares in Q4 and 214 million for the year with an ongoing buyback program for 2018.

I am recommending an inexpensive 2020 LEAP to give them time to work out all the remaining kinks.

I want to enter this position if we get a post Fed dip to $71.50 and the 200-day average. I am not recommending any offsetting positions to reduce the net debit but I will add one as an option once we have an established position with a positive trend.

Position 3/22/18 with a trade at $71.50
Long Jan 2020 $80 call @ $6.75. No initial stop loss.



CAT - Caterpillar Inc Company Profile

Comments:

No specific news. CAT is holding the recent gains from the fading tariff worries.

Original Trade Description: February 11th.

Caterpillar Inc. manufactures and sells construction and mining equipment, diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives for heavy and general construction, rental, quarry, aggregate, mining, waste, material handling, oil and gas, power generation, marine, rail, and industrial markets. Its Construction Industries segment offers backhoe, compact, track-type, small and medium wheel, knuckleboom, and skid steer loaders; small and medium track-type, and site prep tractors; mini, wheel, forestry, small, medium, and large track excavators; and motorgraders, pipelayers, telehandlers, cold planers, asphalt pavers, compactors, road reclaimers, and wheel and track skidders and feller bunchers. The company's Resource Industries segment provides electric rope and hydraulic shovel, landfill and soil compactor, dragline, large wheel loader, machinery component, track and rotary drill, electronics and control system, work tool, hard rock vehicle and continuous mining system, scoop and hauler, wheel tractor scraper, large track-type tractor, and wheel dozer products; longwall, highwall, and continuous miners; and mining, off-highway, and articulated trucks. Its Energy & Transportation segment offers reciprocating engine powered generator set and engine, integrated system, turbine, centrifugal gas compressor, diesel-electric locomotive and component, and other rail-related products and services. The company's Financial Products segment offers finance for Caterpillar equipment, machinery, and engines, as well as dealers; property, casualty, life, accident, and health insurance; and insurance brokerage services, as well as purchases short-term trade receivables. Its All Other operating segments provides parts distribution and digital investments services. The company was formerly known as Caterpillar Tractor Co. and changed its name to Caterpillar Inc. in 1986. Company description from FinViz.com.

CAT has been alternately ignored or talked down for the last couple years but the shares keep rising. Part of the recent gains came from the guidance. The company has been bitten by the global slowdown in construction since the financial crisis. Then it was hit by the slowdown in the energy sector. Every expected rebound falied to appear and CAT continued to give cautious guidance. That changed over the last several months.

The global economy is rebounding. There are massive construction projects now underway in China and Asia. The Eurozone is also seeing a resurgence in consrtuction. Commodity metals are booming and mines are reopening shuttered capacity and opening new mines. Everything is suddenly positive for CAT.

CAT said sales for Q4 rose 35% on strong global demand for construction equipment. They reported earnings of $2.16 compared to estimates for $1.79. Revenue of $12.9 billion beat estimates for $11.9 billion. The company guided for 2018 earnings of $8.25-$9.16 and analysts were expecting $8.19. The CEO said demand remains strong thanks to rising oil prices, booming construction and a rapidly rising global economy. CAT reported before the open on Thursday and shares were volatile over the last two days. However, despite the volatility shares are only down about $2 from the pre-earnings close.

Given CAT's big rally over the last six months, it was no surprise to see the stock sell off sharply. However, shares found support at $142 and the 100-day average at $144.

Update 9/9: Deutsche Bank issued a buy rating because of a rising equipment upgrade cycle in mining and energy. The analyst said an above average upgrade cycle could lead to a 30% increase in revenues in coming quarters with oil and gas revenues rising 10%.

The analyst said CAT was trading at a 45% discount to the S&P and the biggest discount in 20 years.

Update 9/30: CAT won a dismissal of the suit claim it had misled shareholders about risk in using foreign subsidiaries to avoid taxes. The suit came after CAT was raided in March 2017 by the IRS, Dept of Commerce and FDIC. They claim CAT owes $2.3 billion in taxes and penalties because it shifted profits to a Swiss subsidiary to avoid paying U.S. taxes. CAT shares faded slightly from the prior week's gains.

Position 2/12/18:
Long Jan $160 call @ $14.48, see portfolio graphic for stop loss.
Closed 7/9: Short Jan $185 call @ $5.51, exit .68, +$4.83 gain.
Net debit $8.97.



CGC - Canopy Growth - Company Profile

Comments:

Canopy has secured supply contracts for about 35% of expected demand in Canada. Marijuana for recreational uses becomes legal on October 17th. The current US Farm Bill will legalize CBD and Canopy is one of the largest CBD producers in the world. Two additional states have marijuna legalization on the ballot in November and 8 states have already made it legal. Constellation Brands currently owns 38% of Canopy and has warrants that will allow them to take control with more than a 50% stake over the next three years.

Original Trade Description: Sept 23rd.

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, Bedrocan Canada, CraftGrow, and Foria brand names. It also offers its products through Tweed Main Street, a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada. Company description from FinViz.com.

The cannabis sector is on fire and nobody knows how to play it because of the volatility. There will be downs as the rules are drawn and additional countries go all in on recreational use. Canada has approved recreational use starting in October for the entire country. Numerous U.S. states have passed new laws approving the use. Multiple countries have been legal for years but dozens are considering it today.

Tilray (TLRY) has been getting all the news because of its wild swings on only 17.8 million shares outstanding. Tilray is actually the smallest of the big three marijuana producers.

The other two are Canopy Growth (CGC) and Aurora Cannabis (ACBFF). Aurora also traded 15 million shares on Friday but they have 950 million shares outstanding. Canopy traded 11 million against 228 million outstanding.

Aurora is expected to produce 570,000 kilos of weed in 2019 and Canopy is expected to produce more than 500,000 kilos. Tilray said it would only produce 76,000 kilos in 2018 and 150,000 in 2019.

All three of these companies are primarily in weed today but they are rapidly moving to the CBD oils, which have a more mainstream use. Coke is looking at making drinks with CBD oil. Constellation Brands (STZ) is looking at making drinks and edibles with THC, the active ingredient in marijuana. Constellation made a $4.1 billion investment in Canopy with the option to buy more. With big money and big marketing behind Constellation and Canopy I am picking them to be the long term winner.

Look how far the legalization of marijuana has come in just the last two years. Where will the business be two years from now? This is truly a "sky's the limit" potential. The tobacco companies have not yet entered the sector and the most likely entry would be the acquisition of one of these companies. There is eventually going to be a land rush as everyone interested tries to get a piece of this sector starting with the growers.

If yo look at the chart is is going to scare you. The recent spike was the $4.1 billion investment by Constellation. I would not be surprised to see the stock pull back to the uptrend around $40 and if it does we will close the short call for a gain.

Because of the interest in the sector, Canopy has LEAPS out in 2021. That is very long-term and should get us past all the initial volatility. Ideally, I would like to eliminate that short call at some point in the future if we see a material decline in the sector.

Position: 9/24:
Long Jan 2021 $50 LEAP Call @ $20.30, see portfolio graphic for stop loss.
Short Jan 2021 $75 LEAP Call @ $14.80, see portfolio graphic for stop loss.
Net debit $5.50.


CSCO - Cisco Systems - Company Profile

Comments:

No specific news. Shares down slightly after the Nasdaq crash.

Original Trade Description: Aug 26th

Cisco Systems, Inc. designs, manufactures, and sells Internet Protocol (IP) based networking and other products related to the communications and information technology industry worldwide. The company offers switching products, including fixed-configuration and modular switches, and storage products that provide connectivity to end users, workstations, IP phones, wireless access points, and servers; and next-generation network routing products that interconnect public and private wireline and mobile networks for mobile, data, voice, and video applications. It also provides collaboration products comprising unified communications products, conferencing products, collaboration endpoints, and business messaging products; data center products, such as blade and rack servers, series, fabric interconnects, and management software solutions; wireless products consisting of wireless access points, WLAN controllers, cloud and appliances based services, and integrated software services. In addition, the company offers security products, including network and data center security, advanced threat protection, Web and email security, access and policy, unified threat management, and advisory, integration, and managed services; and other products, such as emerging technologies and other networking products. Further, the company offers a distributed file system for hyperconvergence that enables server-based storage systems; service provider video software and solutions; and technical support services and advanced services. It serves businesses of various sizes, public institutions, governments, and service providers. The company sells its products directly, as well as through channel partners, such as systems integrators, service providers, other resellers, and distributors. The company was founded in 1984 and is headquartered in San Jose, California. Company description from FinViz.com.

It appears that everyone is moving to the subscription model for software after the success of companies like Adobe in moving from a sales to a license subscription model. Microsoft Office, Autodesk, even BlackBerry is moving to a subscription model.

Cisco is moving to a subscription model on their highest capacity routers and switches. These devices cost from tens of thousands of dollar to hundreds of thousands. These are Cisco's highest capacity and smartest devices. However you need a masters in device programming to make them work correctly. With cyber security threats growing daily, enterprise users want to be able to stop the majority of the threats at the router level.

Cisco now sells multiyear software as a service (SaS) subscriptions for these top of the line devices. The CEO said the unbilled revenue for SaS subscriptions was their fastest growing revenue line item even though it is not on their books. If someone signs a 3-year service contract, Cisco can only recognize the revenue from the current quarter, and then defers revenue for the rest of the fiscal year. The revenue in future years is not disclosed. Deferred and unbilled revenue was up 28% for the quarter and she said unbilled portion was the largest component.

The reported earnings of 70 cents compared to estimates for 69 cents and earning only 48 cents in the year ago quarter. Revenue rose $700 million to $12.84 billion. Analysts expected $12.77 billion. For the current quarter they guided for 70-72 cents on revenue of $12.74-$12.99 billion. Analysts were expecting 69 cents and $12.58 billion.

I believe Cisco is on the verge of a breakout and a long awaited move higher. Cisco has been dead money all year after a surge in Q3/Q4 last year. This consolidation period may be about over.

Because of the 4.7 billion outstanding shares, the options are inexpensive and we can reach out to 2020 and capture all of the 2019 gains.

Update 9/23: Cisco announced a quarterly dividend of 33 cents payable Oct 24th to holders on Oct 5th. Shares rallied into Friday's close because of the increased weighting in the reformatted XLK ETF after the removal of Google, Facebook and Netflix. Microsoft and Cisco both saw big weighting revisions.

Position 8/27/18:
Long Jan 2020 $50 Call @ $3.25, see portfolio graphic for stop loss.


ECA - Encana Corp - Company Profile

Comments:

No specific news. Shares continue to move in sync with crude prices.

Original Trade Description: May 21st.

Encana Corporation, together with its subsidiaries, engages in the exploration, development, production, and marketing of natural gas, oil, and natural gas liquids in Canada and the United States. The company owns interests in various assets, such as the Montney in northern British Columbia and northwest Alberta; Duvernay in west central Alberta; and other upstream operations, including Wheatland in southern Alberta, Horn River in northeast British Columbia, and Deep Panuke located offshore Nova Scotia. It also holds interests in assets that comprise the Eagle Ford in south Texas; Permian in west Texas; San Juan in northwest New Mexico; Piceance in northwest Colorado; and Tuscaloosa Marine Shale in east Louisiana and west Mississippi. Company description from FinViz.com.

Encana reported earnings of 11 cents that beat estimates for 4 cents. Revenue of $1.297 billion also beat estimates for $789 million. Production declined 18% due to low prices and depletion. This was an excellent report from a beaten down energy stock.

Production averaged 237,100 Boepd. Drilling and completion costs declined by 30%. They reduced long-term debt by $1.1 billion and net debt by 50%. They replaced 326% of production.

They currently have more than 10,000 premium drilling locations and expect to grow that number in 2017. Since December 31st, they have added more than 50 premium locations in the Eagle Ford alone. They ended 2016 with a whopping $5.3 billion in liquidity and cash of nearly $1 billion. They expect to spend $1.6 to $1.8 billion on capex in 2017 and grow liquids production by 35%. Capex willbe funded by cash on hand. Proved reserves were 920 million barrels and 3P reserves were 2.372 billion barrels.

With the cash, production rates, reserves and drilling inventory listed above they are definitely an acquisition candidate with only a $10 billion market cap. Half their market cap is cash on hand.

JP Morgan initiated coverage with an overweight rating and $16 price target.

I am recommending two positions for Encana. I am recommending a January $12 call for $1.40 and a January 2019 $15 call, also $1.40. The short-term position is to capture the expected summer rebound in oil prices. The long-term position is acquisition insurance. It will capture any normal rise in price but also any acquisition announcement.

Oil prices typically peak in August and then decline into fall. If OPEC announces this week an extended production cut scenario through March 2018 as expected, prices could continue to rise into winter as global inventories decline.

Update 8/3: Encana spiked to a 6-month high after reporting earnings of 21 cents that beat estimates for 10 cents. Revenue of $983 million missed estimates because of lower gas prices, lower gas production and higher processing costs. Production averages 337,900 Boepd compared to 316,000 Boepd in the year ago quarter. Natural gas production declined 4% while liquids production rose 24% to 155,300 bpd. Encana is successfully transitioning away from natural gas and into oil and liquids.

Position 5/22/17:

Long Jan 2019 $15 call @ $1.40, see portfolio graphic for stop loss.

Position 8/28/17:
Long (2) Jan 2019 $15 calls @ .50.
Adjusted 2019 position (3 contracts) @ 80 cents each.

Position 10/30/17:
Long (3) Jan 2019 $15 calls @ $1.10.
Adjusted 2019 position (6 contracts) @ .95 each.

Position 3/19/18:
Long Jan 2020 $12 LEAP Call @ $2.35, see portfolio graphic for stop loss.

Previously Closed 1/16: Long Jan 2018 $12 call @ $1.50, exit $2.05, +.55 gain.


GE - General Electric - Company Description

Comments:

GE shares exploded higher after the CEO was unexpectedly replaced with Larry Culp. Shares posted their best week since March 2009. Shares rallied from $11.29 to $13.20.

We added four contracts of the 2020 $18 LEAP calls at the open on Monday at a cost of 40 cents each to bring our average cost in the position to 80 cents per contract.

Original Trade Description: January 21st

General Electric Company operates as an infrastructure and technology company worldwide. Its Power segment offers gas and steam power systems; maintenance, service, and upgrade solutions; distributed power gas engines; water treatment, wastewater treatment, and process system solutions; and nuclear reactors, fuels, and support services. The company's Renewable Energy segment provides wind turbine platforms, and hardware and software; onshore and offshore wind turbines; and solutions, products, and services to hydropower industry. Its Oil & Gas segment offers surface and subsea drilling and production systems, and equipment for floating production platforms; and compressors, turbines, turboexpanders, reactors, industrial power generation, and auxiliary equipment. The company's Aviation segment designs and produces commercial and military aircraft engines, integrated digital components, and electric power and mechanical aircraft systems; and provides aftermarket services. Its Healthcare segment offers diagnostic imaging and clinical systems; products for drug discovery, biopharmaceutical manufacturing, and cellular technologies; and medical technologies, software, analytics, cloud solutions, and implementation services. The company's Transportation segment provides freight and passenger locomotives, and rail and support advisory services; and parts, integrated software solutions and data analytics, software-enabled solutions, mining equipment and services, and marine diesel and stationary power diesel engines and motors, as well as overhaul, repair and upgrade, and wreck repair services. Its Energy Connections & Lighting segment offers industrial, grid, power conversion, automation and control, lighting, and current solutions. The company's Capital segment provides industrial and energy financial services; and commercial aircraft leasing, financing, and consulting services. General Electric Company was founded in 1892 and is based in Boston, Massachusetts. Company description from FinViz.com.

GE has been having a hard time. The financial crisis killed GE Capital and forced them out of that business to drop their SIFI designation and government oversight. They bought Baker Hughes at almost the top of the oil market. Competition is flourishing in every sector. The prior CEO, Jeffrey Immelt left the company under a cloud. They are selling off unprofitable or low profit divisions but the stock just keeps falling. Shares are currently at a 7 year low.

However, while things have been rocky, the new CEO is determined to right the ship. Nobody reading this play description thinks GE is going under. They are a huge manufacturing company with assets in transportation, railroads, aerospace, power, energy, etc.

This is what it driving this recommendation. There are strong rumors and forecasts that GE could be split up into 3-4 companies in a massive restructuring program. Other divisions could be sold to reduce the overall management complexity. There is tremendous value in GE and the new CEO has pledged to unlock it.

With the stock at a 7-year low at $16, this is the target low for a large number of analysts. It could go lower but GE is now a strong value proposition. It is not likely to happen this quarter or even this year, but it will recover. The options are cheap and with earnings on Wednesday, there could be some positive surprises.

With GE in crash mode, I am also recommending a March $16 put. If the stock drops another couple of bucks post earnings, we could sell the put and further reduce our cost in the LEAP.

The LEAP options are cheap. Buy a couple contracts and put them in your "do not disturb" folder. Other traders think this is a good idea as well. More than 4,500 contracts were bought on Friday with another 4,700 contracts of the $20 LEAPs.

Update 9/9: UBS cut the price target from $16 to $13 which ties them with Vertical Research Partners for the second lowest. JP Morgan has the lowest at $11. Analyst claim the power division is dragging down margins and profits.

Position 1/22/18:
Long Jan 2020 $18 LEAP Call @ $2.42, see portfolio graphic for stop loss.
Position 10/1/18:
Long (4) Jan 2020 $18 LEAP Calls @ .40.
Average cost .80.

Prior Positions:
6/15: Expired Long Jun $13 Put @ .71, expired, -.71 loss.
4/02: Closed Long Apr $14 put, entry @ 50 cents, exit $ .92, +.42 gain.
2/20: Closed Long Mar $16 put, entry @ 75 cents, exit $1.33, +.58 gain.



HPQ - HP Inc - Company Description

Comments:

On Wednesday after the close HPQ issued guidance for 2019 for earnings of $2.12-$2.22 and said they were raising the dividend by 15%. Analysts were expecting $2.15. They expect to return 50% to 75% of 2019 free cash flow to shareholders as dividends and share buybacks. They said 2018 had been a strong year for HP and 2019 was expected to be even better. They said demand was strong in the PC sector and across all their other product lines. Shares spiked to a new high at $27 then fell back to earth at $25 on the Nasdaq crash.

Original Trade Description: January 28th

HP Inc. provides products, technologies, software, solutions, and services to individual consumers, small- and medium-sized businesses, and large enterprises, including customers in the government, health, and education sectors worldwide. It operates through Personal Systems and Printing segments. The Personal Systems segment offers commercial personal computers (PCs), consumer PCs, workstations, thin clients, commercial tablets and mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services for the commercial and consumer markets. The Printing segment provides consumer and commercial printer hardware, supplies, media, solutions, and services, as well as scanning devices; and laserJet and enterprise, inkjet and printing, graphics, and 3D printing solutions. The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California. Company description from FinViz.com.

Hewlett Packard, now HP Inc, saw its shares crash back to $9 in 2016 as Lenovo cornered the cheap laptop market and consumers were moving away from desktop PCs. That was a lifetime ago in the tech world. Since that cycle low, HP has reinvigorated itself and changed its business model. The company no longer competes in the cheap computer market. HP now sells top end PCs to compete with the Apple Macs and fully features Dell workstations.

The reinventing of HP has worked. According to IDC, HP's market share rose from 21,8% to 23.5% in the last quarter. Only three companies, HP, Dell and Apple, saw shipments rise in Q4. HP shipments rose 8.3% to 16.6 million, Apple shipped 7.3% more to 5.8 million and Dell barely made the list with a 0.7% rise to 11.1 million. Total PC shipments rose only 0.7% in the quarter, showing how dominant HP was in stealing market share. That was the first quarter where overall PC sales have risen in the last six years. The PC is coming back to life.

Update 9/16: HPQ announced the world's most advanced 3D metal printing system. They claim the system is now 50 times more productive at a significantly lower cost. They also announced their new Metal Jet Production Service to allow manufacturers to upload their CAD designs and have the parts printed on HP equipment. This is a major breakthrough for HPQ and shares should continue higher. They have partnered with GKN and their various divisions. They produce more than 3 billion component parts per year and expects to print MILLIONS of HP Metal Jet parts in 2019.

Position 1/29/18:
Long Jan 2019 $25 call @ $2.13, see portfolio graphic for stop loss.

Position 2/12/18:
Long Jan 2019 $25 call @ 85, average cost now $1.49.



KR - Kroger - Company Profile

Comments:

Kroger and Walgreens formed a partnership to work together in a pilot program. Walgreens will begin selling Kroger products in 13 stores and allow custoemrs to pick up Kroger orders at its stores. Walgreens has about 9,800 stores and Kroger 2,800. I would not be surprised to see Kroger eventually sell its drugs business to Walgreens if the partnership works out. Kroger could pick up 9,800 outlets while Walgreens could gain 2,800 outlets. Since Walgreens has three times the market cap of Kroger, I would also not be surprised to see Kroger bought by the drugstore chain.

Original Trade Description: Sept 16th.

The Kroger Co., together with its subsidiaries, operates as a retailer in the United States. It also manufactures and processes food products for sale in its supermarkets. The company operates supermarkets, multi-department stores, jewelry stores, and convenience stores. Its combination food and drug stores offer natural food and organic sections, pharmacies, general merchandise, pet centers, fresh seafood, and organic produce; multi-department stores provide general merchandise items, such as apparel, home fashion and furnishings, outdoor living, electronics, automotive products, toys, and fine jewelry; and price impact warehouse stores offer grocery, and health and beauty care items, as well as meat, dairy, baked goods, and fresh produce items. The company's marketplace stores comprise full-service grocery, pharmacy, health and beauty care departments, and perishable goods, as well as general merchandise, including apparel, home goods, and toys; and convenience stores comprise a limited assortment of staple food items and general merchandise, as well as sells fuel. It operates under the banner brands, such as Kroger, Ralphs, Fred Meyer, King Soopers, etc., as well as Simple Truth and Simple Truth Organic brands. As of March 8, 2018, the company operated 2,800 retail food stores under various banner names, as well as an online retail store. The Kroger Co. was founded in 1883 and is based in Cincinnati, Ohio. Company description from FinViz.com.

Kroger reported Q2 earnings and beat by a penny but revenue barely missed estimates. Kroger reported earnings of 41 cents compared to estimates for 29 cents. Revenue of $27.9 billion rose 1.8% but was just below estimates for $30.0 billion. Same store sales rose 1.6% but missed estimates for 1.8%. Shares were knocked for a 12% drop. Really, were the results that bad? No.

Kroger is only two quarters into their "Restock Kroger" restructuring program where they are remodeling the majority of the stores, changing the product mix and making the stores more inviting. They are spending a lot of money to prepare for the future.

Here is a key point. Online sales rose 50%. How many other retailers can make that claim? They are now selling their organic Simple Truth brand in Asia through Alibaba's Tmall. They just launched Kroger Ship and expanded their Instacart offering.

They guided conservatively for gull year same store sales to rise 2.0-2.5% and for earnings of $2.00-$2.15. Analysts were expecting $2.12 and that is where the stock crash was created.

For a company that is remodeling 2,800 stores and spending money to improve its future results, I think this decline was overkill.

Fortunately, it deflated the option prices significantly. We can buy a 2020 call for $2.57 that was in the money early last week. Kroger is not a chart ripper and it will not be $50 in January but it could be over $50 in Jan 2020 or higher as these merchandising efforts begin to bear fruit.

I hate to buy LEAPS on stocks that are breaking out or have already had a good run. I would rather buy LEAPS on stocks that have stumbled. I think this is a buying opportunity. I hope support at $28 holds but I am recommending an October put just in case as insurance.

Update 9/30: IGD said in a research report that the U.S. grocery retail market would rise to $1.7 trillion by 2022. The online grocery delivery market is expected to grow to $20 billion over that same period. That equates to a 18.1% annual rise for online sales. Kroger is building out 20 distribution centers to handle this surge in business.

Position 9/17/18:
Long Jan 2020 $30 LEAP Call @ $2.70, see portfolio graphic for stop loss.
Long Oct $27 put @ 48 cents, see portfolio graphic for stop loss.


MCD - McDonalds Company Profile

Comments:

McDonalds shares moved sideways after Amazon raised the minimum wage to $15. Bernie Sanders immediately demanded that McDonalds also match the $15 price.

Original Trade Description: February 25th.

McDonald's Corporation operates and franchises McDonald's restaurants in the United States, Europe, the Asia/Pacific, the Middle East, Africa, Canada, Latin America, and internationally. The company's restaurants offer various food products, soft drinks, coffee, and other beverages. As of December 31, 2016, it operated 36,899 restaurants, including 31,230 franchised restaurants comprising 21,559 franchised to conventional franchisees, 6,300 licensed to developmental licensees, and 3,371 licensed to foreign affiliates; and 5,669 company-operated restaurants. Company description from FinViz.com.

McDonalds has revitalized their menu and now offers fresh burgers rather than frozen, all day breakfasts, inexpensive drinks, healthier sides and reasonable prices. This is not your father's McDonalds.

Same store sales in the last quarter rose 5.5%, which is unheard of for a fast food chain the size of McDonalds. The CEO said, "We're building a better McDonald's and more customers are noticing. Our relentless commitment to running great restaurants and keeping the customer at the center of everything we do is generating broad-based strength and momentum across our entire business."

Their latest surprising innovation is food delivery. They have partnered with multiple mobile delivery services and business is booming. McDonalds said delivery orders were significantly larger than dine in or take out because people now realize they can order for parties, football games, family dinners, etc. They order multiples of everything and the average check is significantly higher than a dine in order.

They are also implementing mobile ordering and payment with the order. You just show up and pick up your meal and it is ready to go. No lines to pay, no waiting for your food. They will have mobile order/pay in more than 20,000 stores by the end of 2017. The CEO said they were also seeing higher check sizes of 1.2x to 2.0x when mobile ordering is used.

McDonalds said it was going to sell some of the McCafe beverages in supermarkets in early 2018 through a partnership with Coca Cola. The company also announced three new espresso drinks for its own stores. They are Carmel Macchiato, Cappuccino and Americano. They are going to rebrand the McCafe offerings with a new logo and packaging. They are rolling out new coffee makers to nearly all of their 14,000 stores.

A consumer research company said sales at McDonalds were soaring in states that had legalized marijuana. They said 43% of users were eating at McDonalds, 18% Taco Bell, 17.8% Wendy's and 17.6% Burger King in order to satisfy their munchies after smoking pot. A side effect of marijuana is increased appetite.

Jefferies upgraded McDonalds (MCD) saying the partnership with Uber Eats will continue to push sales higher. McDonalds has said their delivery orders have a higher average ticket than traditional on site orders. Jefferies raised the price target from $150 to $200. The company restarted its dollar menu in January and there are $1, $2 and $3 items on the menu. An example would be any size drink or cheeseburger for $1, McDoubles and small McCafe drinks for $2 and Happy Meals and triple cheeseburgers for $3.

Update 9/23: McDonalds (MCD) announced a 15% hike in the quarterly dividend from $1.01 to $1.16. This is the 42nd consecutive year that McDonalds has hiked the dividend. It is payable on Dec 17th to holders on Dec 3rd. In prior years and counting backwards McDonald hiked the dividend by 7% in 2017, then 6%, 5%, 5%, 10%, 15% and 11% in 2010. The company said it has the capital allocation flexibility this year thanks to its booming business and the tax cuts. So far, in 2018 the company has paid $1.6 billion in dividends and bought back $3.3 billion in stock. Shares spiked $4.50 on the news.

Update 9/30: McDonalds said it was removing the artificial ingredients from its burgers, chicken nuggets and will use cage free eggs by 2025. As of today about two-thirds of burgers and sandwiches have no artificial preservatives, flavors or colors. Only the pickle has an artificial preservative. Shares rose to a new 4-month high.

Position 2/26/18:
Long Jan $170 call @ $8.52, see portfolio graphic for stop loss.

Previously closed 8/20: Short Jan $190 call @ $2.79, exit .43, +$2.36 gain.



MRK - Merck & Co - Company Description

Comments:

Merck announced positive trial data on HIV-1 drug Delstrigo

Original Trade Description: November 12th

Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also offers neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. Additionally, the company offers companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; AstraZeneca PLC.; and SELLAS Life Sciences Group Ltd. The company serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Company description from FinViz.com

Merck reported earnings of $1.11 compares to the $1.03 that analysts expected. Revenue of $10.33 billion beat estimates. The company guided for full year earnings of $1,.78-$1.84 up from $1.60-$1.72. Revenue guidance rose from $39.4-$40.4 billion to $40.0-$40.5 billion.

Shares were crushed after the company said it had pulled its European application for the cancer drug Keytruda. Sales of the drug nearly tripled to $1.05 billion where it has already been approved and are expected to continue to grow to $5 billion over the next two years.

The reason they pulled the European application was to modify a phase III trial to focus on "overall survival" or OS rather than short-term "progression free survival" or PFS. This pushed the trial end date out to early 2019. Overall survival is the holy grail of any cancer drug. It is one thing for cancer to grow slower and let the patient live a longer life but gaining another 6-12 months of life is a fleeting goal. Living out your normal life span is the target all drugs shoot for. By modifying the trial to focus on longer term benefits, the eventual drug approval will be worth more. If the short term drug is worth $10,000 per treatment, a drug that give you upir life back is worth 10 times or even a 100 times that amount.

Merck will refile the application when they have the new data but this is one drug with $3 billion a year in sales compared to their current $40 billion in overall volume. If they get the OS data they want, Keytruda could grow to $10 billion a year by 2022.

I believe this drop is a buying opportunity because the LEAP premiums are miniscule for a company with a $150 billion market cap and $40 billion in annual sales.

Update 7/29: Merck reported earnings of $1.06 that beat estimates by 3 cents. Revenue was $10.47 billion and beat estimates for $10.32 million. Prescription drug sales rose 6% to $9.28 billion led by Keytruda, Januvia and Gardasil. U.S. drug sales fell 3% while international sales rose 13%. Zostavax and Hep-C drug Zepatier both saw sales decline more than 70% as more drugs hit the market and competition becomes fierce.

Keytruda is expanding its base and is now approved for eight different cancer types. The drug was just approved last week in China, which has a serious melanoma problem. Sales of Keytruda are expected to reach $22 billion a year by 2022. The company raised full year earnings guidance from $4.16-$4.28 to $4.22-$4.30. Revenue is expected to range between $42.0-$42.8 billion, up slightly from the prior $41.8-$43.0 billion guidance. Analysts thought this guidance was weak and shares fell sharply at the open.

Update 9/9: The FDA granted MRK a priority review on using Keytruda on a rare form of skin cancer. In a study with 14 patients 64% responded well to the treatment and all 14 saw tumor shrinkage.

Position 11/13/17:

Long Jan 2019 $60 LEAP Call @ $2.38, see portfolio graphic for stop loss.
Long Jan 2020 $60 LEAP Call @ $3.90, see portfolio graphic for stop loss.


MSFT - Microsoft Company Profile

Comments:

Widespread rumors of a bug in Windows 10 that deletes a users profile and all associated data could put pressure on shares next week.

Original Trade Description: March 11th

Microsoft Corporation develops, licenses, and supports software products, services, and devices worldwide. The company's Productivity and Business Processes segment offers Office 365 commercial products and services for businesses, including Office, Exchange, SharePoint, Skype for Business, and related Client Access Licenses (CALs); Office 365 consumer services, such as Skype, Outlook.com, and OneDrive; Dynamics business solutions, such as financial management, enterprise resource planning, customer relationship management, supply chain management, and analytics applications for small and mid-size businesses, large organizations, and divisions of enterprises; and LinkedIn online professional network. Its Intelligent Cloud segment licenses server products and cloud services, such as Microsoft SQL Server, Windows Server, Visual Studio, System Center, and related CALs, as well as Azure, a cloud platform; and enterprise services, such as Premier Support and Microsoft Consulting that assist in developing, deploying, and managing Microsoft server and desktop solutions, as well as provide training and certification to developers and IT professionals on Microsoft products. The company's More Personal Computing segment comprises Windows OEM, volume, and other non-volume licensing of the Windows operating system; patent licensing, Windows Internet of Things, MSN display advertising, and Windows Phone licensing system; devices, including Microsoft Surface, phones, and PC accessories; and search advertising, including Bing and Bing Ads. This segment also provides gaming platforms, including Xbox hardware, Xbox Live, video games, and third-party video games. The company markets and distributes its products through original equipment manufacturers, distributors, and resellers, as well as through online and Microsoft retail stores. Microsoft Corporation has a strategic partnership with CNH Industrial N.V. The company was founded in 1975 and is headquartered in Redmond, Washington. Company description from FinViz.com.

Microsoft has broken out after years of lethargy as a designer of Windows operating systems. Every couple of years they would release a new version and revenue would pop for the next 12 months as people upgraded. As the systems became more stable, the number of people upgrading began to decline. With the help of the new CEO that has changed.

Now they are moving to a subscription software as a service model on the Office products and versions of their new products. They moved into the cloud with Azure and a handful of cloud offerings. They are expanding into service relationship with enterprise customers. Their Windows Surface tablets have caught fire. The Xbox family of products continues to expand.

They are no longer just an operating system and database company. The stock closed at a new high on Friday and seems destined to move a lot higher. Twenty years ago you could always buy Microsoft and never go wrong because they always went up. After being dormant from 2001-2012 the stock has begun a multiyear rally but a lot of people are ignoring their newfound prosperity because they are remembering the 11 years of lethargy.

Update 3/30: The government asked federal prosecutors to dismiss a Supreme Court case against Microsoft demanding access to user data for accounts related to users outside the USA. On March 22nd President Trump signed a new law authorizing government access to overseas data but giving companies an avenue to object. Under the new law there was no reason to continue the old case.

There are rumors Microsoft will begin charging more for Windows operating systems on higher end computers. An inexpensive desktop or notebook with minimal capacity would be charged less than a fully featured PC with high end components like processors, video cards and high speed disks. This would give Microsoft a revenue bump but would likely make a lot of users mad. However, it is not like they can go elsewhere and get a different operating system since 90% of PCs and notebooks run Windows.

Fortunately, because they have 8 billion shares outstanding their options are relatively cheap.

Update 9/2: Alibaba said it was cutting back on plans to expand its cloud business in the U.S. because of competition from Microsoft, Google and Amazon. Their initial efforts have fallen short given the strength of the competitors. They will now focus on providing cloud services for U.S. companies that have significant needs in Asia. They no longer want to compete head to head with U.S. cloud providers. Good move!

Position 3/12/18:
Long Jan $100 call @ $7.03, see portfolio graphic for stop loss.
Optional: Short Jan $80 put @ $2.29, see portfolio graphic for stop loss.
Net debit $4.74.



NTNX - Nutanix - Company Profile

Comments:

We closed this position at the open on Monday.

Original Trade Description: Sept 9th.

Nutanix, Inc. develops and provides an enterprise cloud operating system software. It offers enterprise applications, virtual desktop infrastructure, virtualization and cloud, big data, remote and branch office IT, and data protection and disaster recovery solutions; and hardware platforms and software options; and support and services. The company's products include Acropolis, a hyperconverged infrastructure solution to run any application; Prism, an infrastructure management solution with one-click operations; Nutanix Calm, an application-centric IT automation solution; Xi cloud services; Nutanix Xpress that eliminates the need for clunky SANs, expensive hypervisor licensing, and complex data protection and management software; and tools and technologies. It serves education, energy and utilities, financial services, healthcare, retail, and service provider industries, as well as state and local government, and the United States federal government. Nutanix, Inc. was founded in 2009 and is headquartered in San Jose, California. Company description from FinViz.com.

The company reported a loss of 11 cents for Q2 compared to estimates for a loss of 22 cents. Revenue of $303.7 million rose 20% and beat estimates for $298.6 million. The problem came with the guidance. They expect a loss of 26-28 cents on revenue of $295-$310 million. Analysts were expecting a loss of 23 cents on $309 million. Shares had been near the recent highs and crashed back $13 to $50.

Nutanix is shifting from a hardware sales model at zero margins in order to get their software installed on a subscription basis to a software only model and exiting the hardware business. They can do this because they are over the consumer acceptance stage. They no longer have to "buy" accounts with sweetheart hardware deals. The evolution out of the hardware space is a drag on revenue but revenue at zero margins is not a plus. Getting out of the high revenue low margin business is a plus but it means the revenue numbers will be a challenge for the first year.

Multiple analysts came out in support of Nutanix saying the new long-term subscription offerings should trump the additional capex spending. Raymond James said they anticipate growth acceleration driven by new opportunities in multi-cloud as well as new products. RJ upped their price target from $64 to $74 and the stock is at $50. JMP Securities said the shares are undervalued and the higher capex and sales and marketing expenses were "prudent" due to the large market opportunity.

Stifel remained positive with a $64 target saying "We believe Nutanix will sustain strong double digit software growth in coming years given its expanding product set."

What was not shown in the bare earnings numbers was the 66% YoY growth in software and support billings and 49% YoY growth in software and support revenue. They also generated 78% adjusted gross margin in the shift to a Software-Defined business. Billings rose 37% to $395.1 million. Cash on hand rose 168% to $934.3 million.

They added more than 1,000 customers in the quarter to put their base over 10,000 and they signed their largest deal in history for more than $20 million.

For the current quarter, they guided for revenue growth of 40-45% and billings growth of 50-55% with adjusted margins of 78-79%.

Any company would move the sun and moon to have those kinds of revenue and margin projections. This is why we need to buy Nutanix on the selloff.

Update 9/23: Google denied they were building custom servers and software to compete with Nutanix. The company said "We value our partnerships highly and can confirm we are not competing with our partners in this area." Nutanix is a partner with Google Cloud.

Position 9/10/18:
Closed 10/1: Long Jan 2020 $55 Call @ $11.69, exit $7.30.
Closed 10/1: Short Jan 2020 $75 Call @ $5.49, exit $3.72.
Net loss $2.62.


QCOM - Qualcomm - Company Profile

Comments:

No specific news. Shares faded with the Nasdaq.

Original Trade Description: July 29th

QUALCOMM Incorporated designs, develops, manufactures, and markets digital communication products worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access, and other technologies for use in wireless voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses or provides rights to use portions of its intellectual property portfolio, which include various patent rights useful in the manufacture and sale of wireless products comprising products implementing CDMA2000, wideband CDMA, CDMA time division duplex, and/or long term evolution standards and their derivatives. The QSI segment invests in early-stage companies in various industries, including automotive, Internet of things, mobile, data center, and healthcare for supporting the design and introduction of new products and services for voice and data communications, and new industry segments. The company also provides products and services for mobile health; products designed for the implementation of small cells; development, and other services and related products to the United States government agencies and their contractors; and software products, and content and push-to-talk enablement services to wireless operators. In addition, it licenses chipset technology, and products and services for use in data centers. QUALCOMM Incorporated was founded in 1985 and is headquartered in San Diego, California. Company description from FinViz.com.

The last 12 months have been turbulent for Qualcomm. First they tried to acquire NXP Semiconductor (NXPI). They received approvals from 7 of the 8 countries that needed to approve the transaction. While they were waiting on China's approval, Broadcom (AVGO) made a hostile offer to acquire Qualcomm for $121 billion. Qualcomm would be forced to drop the bid for NXPI if they accepted the Broadcom bid. Qualcomm fought Broadcom and finally got the government to veto the deal under a national security rationale.

Broadcom quickly made a big show of becoming a U.S. company by changing its domicile to the U.S. That was not enough to convince CFIUS they were not a threat. Eventually Broadcom dropped its bid.

Qualcomm tried to continue its acquisition of NXPI but China refused to approve the acquisition and Qualcomm was forced to abandon the acquisition attempt and pay a $2 billion breakup fee.

While Qualcomm and NXPI would have been stronger together, Qualcomm is not sitting still. They are rapidly moving forward on 5G communications, automotive chips, internet connectivity, Internet of Things, network processing, etc.

The company just announced a $30 billion stock buyback. That is one-third of the company using the funds they had set aside for the NXPI acquisition.

The next challenge for Qualcomm is settling the patent dispute with Apple. The phone company has protested the way Qualcomm collects royalties on its products. Instead of only charging a royalty on the specific parts in the phone, Qualcomm has always charged a royalty on the entire cost of the phone. In the beginning, companies did not balk because without Qualcomm's parts the phone would not have been possible. After paying royalties to Qualcomm for years, Apple decided they were paying too much money to Qualcomm and sued them to change the patent. Since Apple and every other phone manufacturer had been paying Qualcomm under this structure for years, Apple does not have a very good chance of winning. They do have a lot of money and the best lawyers in the world but the law is the law and signed agreements are tough to fight.

This suit is expected to be settled later this year. Investors should be looking at Qualcomm as an outstanding investment now that the clouds have cleared.

With a 4% dividend and buying back 33% of the stock, there is no reason for Qualcomm shares not to rise in the coming months. The stock should also be somewhat immune to market movement over the coming weeks thanks to the monster buyback.

Earnings October 24th.

Update 9/2: Shares pulled back slightly after they repurchased 76.2 million shares through a Dutch auction at $67.50 for a total of $5.1 billion. That was 5.2% of the outstanding shares and they have $25 billion remaining on their authorization. Shares are not declining because Qualcomm management expects an end to the Apple suit over the next couple of months. Without that overhang shares could rise sharply.

Update 9/16: Barclay's resumed coverage with an overweight weighting and $95 price target. Qualcomm said it had entered into an accelerated share repurchase program with BAC, C and MS for a minimum of 178 million shares worth an estimated $16 billion. This is part of their previously announced $30 billion repurchase program. They expect to complete the $30 billion in FY 2019.

Update 9/30: A US Trade judge ruled in favor of Qualcomm on a patent case against Apple but refused to block iPhone imports as Qualcomm was demanding. The case will go to review and it is far from over. The judge said the harm to the consumer had to be considered. That does not mean there will not be a big penalty for Apple.

Position 7/30/18:
Long Jan 2020 $70 call @ $5.00, see portfolio graphic for stop loss.


SPY - S&P SPDR ETF - ETF Profile

Comments:

Shares crashed back to the 50-day and horizontal support at $287.

Original Trade Description: Sept 30th.

The SPDR S&P 500 trust is an exchange-traded fund which trades on the NYSE Arca under the symbol SPY. SPDR is an acronym for the Standard & Poor's Depositary Receipts, the former name of the ETF. It is designed to track the S&P 500 stock market index. This fund is the largest ETF in the world.

The SPY has pulled back to the 30-day average and actually a steeper decline than the S&P-500. The SPY is near support at the 30-day average.

I believe the market is going to move higher during the Q3 earnings cycle. Even if we do not see a Q3 earnings rally the long term outlook is positive.

The 12 months after mid-term elections have seen the S&P gain an average of 15% for the last 18 midterms. That is 72 years and the S&P has gone up every time. There are almost no trends in the market that repeat 100% of the time. By recommending this position I have probably jinxed the coming year.

However, with the economy growing at more than 4% GDP, unemployment at record lows and Q3 earnings expected to show 20% growth or better, this should be a good opportunity for the trend to repeat.

If we do get a 15% rally over the next 12 months that would be 45 SPY points. The options are expensive for obvious reasons. I do not want to make it a spread and give up a significant portion of our eventual gains. I am going to recommend an offsetting short put to defray the cost of the call. If you cannot write cash secured puts then you should turn it into a spread by selling the call of your choice.

Position 10/1/18:
Long Jan 2020 $300 Call @ $16.80, see portfolio graphic for stop loss.
Short Jan 2020 $270 Put @ $10.61, see portfolio graphic for stop loss.
Net debit $6.19.


TEVA - Teva Pharmaceuticals - Company Description

Comments:

Teva was upgraded from underperform to market perform at Leerink Partners. Goldman Sachs upgraded the stock to the conviction buy list with a $30 price target. The stock closed at $21.50 on Friday.

Original Trade Description: December 10th

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women's health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson's disease; and Nuvigil for the treatment of excessive sleepiness associated with narcolepsy and certain other disorders. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda/Bendeka, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. This segment also offers a portfolio of products in the women's health category, which includes ParaGard, Plan B One-Step, and OTC/Rx, as well as other products. The company has collaboration arrangements with Attenukine, Procter & Gamble Company, and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. Company description from FinViz.com

Teva is the largest generic drug manufacturer in the world. Unfortunately, that market place is becoming very competitive and the company has to reinvent itself to return to a profitable growth profile.

Fortunately, the company is taking action. They have been selling off noncore assets to pay down debt. They just installed a new CEO,Kare Schultz, and he took immediate action. On his second day on the job, he restructured the management team and said he would present a major restructuring plan in mid December. Last week, the stock jumped to a two-month high after news broke they were considering cutting 10,000 of their 57,000 workers in an effort to save $1.5-$2.0 billion a year.

Shares fell in early November after the company cut full year guidance for the third time and said they may sell shares to reduce their debt. In early December, they pulled back on the share sale idea saying they have no plans for a secondary offering in the near future.

I believe the worst is over. The reaction to the news over the last four months has been horrendous. Shares had fallen from $32 to $10. Since the new CEO took control, they have rebounded back to $16.

Because of the giant drop, the LEAP premiums are very reasonable. I am suggesting we take advantage of the los premiums and the potential for a share price recovery. I am recommending both the 2019 and 2020 strikes. This way we can take some gains in late 2018 and let the longer term bet ride.

Update 8/3: Teva reported earnings of 78 cents that beat estimates for 64 cents. Revenue of $4.7 billion matched estimates but declined $1 billion from the year ago quarter. The company guided for 2018 earnings of $2.55-$2.80, up from $2.40-$2.65 on revenues of $18.5 to $19.0 billion. Shares crashed when sales of its MS treatment declined 50% because of generic competition.

Update 8/19: Teva received approval for a generic EpiPen just as kids go back to school and pens need to be refreshed. There has been a shortage of pens and this approval came at exactly the right time. Shares rocketed higher.

Position 12/11/17:

Long Jan 2019 $20 LEAP Call @ $2.10, see portfolio graphic for stop loss.
Optional: Long Jan 2020 $20 LEAP Call @ $3.70, see portfolio graphic for stop loss.


UTX - United Technologies Company Profile

Comments:

UTX completed the acquisition of S2 Security.

Original Trade Description: June 24th.

United Technologies Corporation provides technology products and services to building systems and aerospace industries worldwide. Its Otis segment designs, manufactures, sells, and installs passenger and freight elevators, escalators, and moving walkways; and offers modernization products to upgrade elevators and escalators, as well as maintenance and repair services. The company's UTC Climate, Controls & Security segment provides heating, ventilating, air conditioning, refrigeration, fire, security, and building automation products, solutions, and services for residential, commercial, industrial, and transportation applications. This segment also offers building services, including audit, design, installation, system integration, repair, maintenance, monitoring, and inspection services. Its Pratt & Whitney segment supplies aircraft engines for commercial, military, business jet, and general aviation markets; and provides aftermarket maintenance, repair, and overhaul, as well as fleet management services. The company's UTC Aerospace Systems segment provides electric power generation, power management, and distribution systems; air data and aircraft sensing systems; engine control, intelligence, surveillance, and reconnaissance systems; engine components; environmental control systems; fire and ice detection, and protection systems; propeller systems; engine nacelle systems; aircraft lighting and seating, and cargo systems; actuation and landing systems; space products and subsystems; and aftermarket services. United Technologies Corporation offers its services through manufacturers' representatives, distributors, wholesalers, dealers, retail outlets, and sales representatives, as well as directly to customers. United Technologies Corporation was founded in 1934 and is headquartered in Farmington, Connecticut. Company description from FinViz.com.

UTX is acquiring Rockwell Collins (ROK). An analyst at Morgan Stanley said the acquisition of Rockwell Collins is proceeding and should close in Q3. The acquisition increases the potential for restructuring and the potential spin off of non-core assets in order to concentrate on the profitable divisions. The analyst believes Rockwell Collins will help lift earnings to $7.60 in 2019 and $8.20 in 2020. The stock was resumed at Morgan Stanley with an overweight rating and $160 price target. Shares closed at $127. Barclays has an overweight rating and $157 price target.

UTX just won a $2 billion deal for the propulsion systems on the F-35 joint strike fighter. This is the 11th award and will support all three variants of the fighter. The award is for 135 engines, production support, program management, engineering support, spare modules and spare parts. This contract is expected to reduce the price of the engines by as much as 3.39% compared to the 10th award.

In Q1 United's revenue rose 18% on the commercial segment and 13% on the military segment.

Earnings July 24th.

Update 7/29: UTX reported earnings of $1.97 that beat estimates of $1.86. Revenue rose 9% to $16.71 billion and beat estimates for $16.27 billion. They raised their full year guidance from $6.95-$7.15 to $7.10-$7.25. They raised revenue guidance from $64.0-$64.5 billion to $63.5-$64.5 billion. Shares spiked on the news.

Position 6/25:
Long Jan $130 call @ $4.31, see portfolio graphic for stop loss.
Optional: Short Jan $145 call @ $.92, see portfolio graphic for stop loss.
Net debit $3.39.

Previously closed: Position 6/18:
Long Jan $130 call @ $5.60, exit $4.85, -.75 loss.
Optional: Short Jan $145 call @ $1.08, exit .84, +.24 gain
Net loss $.51.



XBI - S&P SPDR Biotech ETF - ETF Profile

Comments:

I said I was going to close this position this week if there was no improvement. Unfortunately, we saw a $5 decline because of the Nasdaq crash and our remaining premium fell to only 52 cents. For that price I am willing to continue holding for a potential Q3 earnings rally.

Original Trade Description: Sept 2nd.

The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the "Index")

The ETF seeks to provide exposure to the Biotechnology segment of the S&P TMI, which comprises the Biotechnology sub-industries.

Seeks to track a modified equal weighted index which provides the potential for unconcentrated industry exposure across large, mid and small cap stocks.

The ETF allows investors to take strategic or tactical positions at a more targeted level than traditional sector based investing. ETF description from S&P US.SPDRS.com

Hardly a day goes by that we do not hear of some new treatment to cure some previously untreatable disease. I believe in our kids lifetime we will find a treatment to cure cancer, diabetes, etc or at least reduce the impact to patients afflicted with those diseases.

Ten years ago Hep C was a death sentence. Today 95% of patients can be cured. Not just treated, but cured. Twenty years ago HIV was also a death sentence. Today 75 million people live with the disease with most free of symptoms.

The biotech sector is responsible for the most improvements in our life expectancy and quality of life. These companies, and there are a bunch, are on the cutting edge of disease treatments.

Investing in a single biotech company is a coin toss. You can be riding high one day and 50% poorer the next. Even owning a basket of 3-5 stocks is somewhat dangerous. Owning the curated ETF is the best way to participate. The gains in the majority overcome the weakness in a few.

Biotechs are immune from tariffs so a continued trade war should not impact them directly.

The ETF declined with the Nasdaq in July, since most biotechs are Nasdaq stocks. The ETF has rebounded from that dip and is testing the prior highs.

Position 9/10/18:
Long Jan $105 Call @ $1.88, see portfolio graphic for stop loss.

Previously closed 9/7: Long Jan $105 Call @ $3.50, exit $1.90, -1.60 loss.


XLC - S&P Communication Services ETF - ETF Profile

Comments:

Shares crashed with the 3.2% decline in the Nasdaq.

Original Trade Description: Sept 23rd.

The Communication Services Select Sector SPDR Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of the Communication Services Select Sector Index (the "Index"). The Index seeks to provide an effective representation of the communication services sector of the S&P 500 Index. Seeks to provide precise exposure to companies from the media, retailing, and software & services industries in the U.S. and allows investors to take strategic or tactical positions at a more targeted level than traditional style based investing. Description from State Street Global Advisors.

With FB, Alphabet, ATVI, NFLX, EA, TWTR, TTWO and TRIP all moving to the previously dormant XLC sector ETF, the odds are good that a lot of portfolio managers will shift investments to the ETF in order to be exposed to those stocks.

The downside to this theory is the 15 or so unwanted telephone, newspaper and TV stations in the same ETF. Fortunately, those stocks I listed above make up 59.5% of the ETF so they should control the direction. After seeing the big cap techs decline for no particular reason over the last two weeks it seems obvious now that they were victims of the S&P/MSCI index/ETF restructuring.

There are no leaps so I am using the longest dated option and maybe we will be rewarded with a Q3 earnings rally.

Position 9/24/18:
Long March $50 Call @ $2.30, see portfolio graphic for stop loss.



If you like the trade setups you have been receiving and you are on a free trial then now is the time to subscribe. Don't wait until you miss a newsletter to decide you want to take the plunge.

subscribe now



Prices Quoted in Newsletter

At Option Investor we have a long-standing policy prohibiting the editors and staff from actually trading the individual recommendations in order to conform to SEC rules concerning trades.

The prices quoted in the newsletter are the end of day prices in most cases.

When discussing fills or stops the prices quoted are the bid/ask at the time the entry trigger or exit stop is hit. This is NOT a price that someone on staff actually got using a live order.

For entry/exit points at the market open the prices quoted will be the opening print. The majority of the time readers are able to get a better fill than the opening print because of market maker bias at the open.

For trades with an opening qualification the prices quoted will be the bid/ask at the time the qualification was met.

All of these rules normally produce worse prices than an active trader would normally get. Because they are standardized there may be some cases where a price quoted was better than an actual fill. If you received a price that was dramatically different than what was quoted please let us know.